Predicting the Progression of Heart Failure to Inform Care | Penn Precision Medicine

Predicting the Progression of Heart Failure to Inform Care | Penn Precision Medicine

Predicting the Progression of Heart Failure to Inform Care | Penn Precision Medicine

About 5.7 million people in the United States have heart failure, which occurs when the heart cannot pump enough blood and oxygen to support other organs in the body. Heart failure is a chronic disease, however, with treatment, signs, and symptoms can improve. To ensure each patient receives the right treatment at the right time, a team at Penn Medicine launched a project in which they are using a set of fatty acid metabolites called acylcarnitines as biomarkers to differentiate heart failure patients. By combining acylcarnitines with clinical-based parameters, the team developed algorithms to track and accurately predict which patients may progress rapidly in their disease courses. The information will enable clinicians to tailor decisions on the timing of pharmaceutical treatment or advanced surgical therapies, such as left-ventricular-assisted-device placement or heart transplant.

Learn more about this Precision Medicine project: https://www.pennmedicine.org/news/new…

Learn More About Doctor Wang:
https://www.med.upenn.edu/apps/facult…

#HeartFailure #PrecisionMedicine #PennMedicine


Content

0.305 -> (gentle music)
6.89 -> - How many times every day
8.42 -> do you use your fingerprint to unlock your smartphone?
11.53 -> Each of us has a unique fingerprint or signature
14.77 -> that we use to verify our identity
17.05 -> or customize personal choices suitable to our lifestyles.
20.69 -> What if we could use a fingerprint
22.41 -> to customize treatment for each heart failure patient?
25.32 -> Imagine tracking and accurately predicting
28.1 -> when the heart will deteriorate further
30.3 -> and when placement of a left ventricular assistive device
34.21 -> or heart transplantation
35.83 -> is optimally timed to give the patient the most benefit
39.37 -> while avoiding unnecessary risks and side effects.
42.75 -> It turns out,
43.583 -> we may already carry this unique signature in our blood.
46.67 -> The key lies in the metabolites of fatty acids oxidation
50.04 -> called acylcarnitines.
51.56 -> Using multiplexed mass spectrometry assays,
54.18 -> we found associations
55.153 -> between the pattern of acylcarnitines
57.74 -> and clinical characteristics and outcomes
60.67 -> in heart failure patients.
62.33 -> By combining acylcarnitines with clinical parameters,
65.43 -> we have developed machine learning-based algorithms
68.16 -> to predict progression time
70.24 -> to advanced interventions for each patient.
72.76 -> We're fine tuning the signature
74.49 -> by adding more acylcarnitine information
76.65 -> as the disease progresses.
78.76 -> This will enable us
79.94 -> to continuously monitor, track, and predict
82.96 -> each patient's heart condition
84.56 -> and customize either surgical or pharmaceutical treatment
88.39 -> based on his or her unique blood signature.
91.36 -> 5.7 million people live with heart failure
94.15 -> in the United States,
95.31 -> and 500,000 of them are in advanced stage,
98.36 -> refractory to standard treatment.
100.76 -> Our precision medicine-based approach
102.65 -> aims to give them the right treatment at the right time.
105.95 -> I am Dr. Ping Wang,
107.17 -> and this is precision medicine at Penn.

Source: https://www.youtube.com/watch?v=StFdAJSBXuw